L-PZQ ODT 50 mg/kg + Biltricide® + L-PZQ ODT 60 mg/kg
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Schistosomiasis
Conditions
Schistosomiasis
Trial Timeline
Sep 2, 2019 → Oct 11, 2021
NCT ID
NCT03845140About L-PZQ ODT 50 mg/kg + Biltricide® + L-PZQ ODT 60 mg/kg
L-PZQ ODT 50 mg/kg + Biltricide® + L-PZQ ODT 60 mg/kg is a phase 3 stage product being developed by Merck for Schistosomiasis. The current trial status is completed. This product is registered under clinical trial identifier NCT03845140. Target conditions include Schistosomiasis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03845140 | Phase 3 | Completed |
Competing Products
3 competing products in Schistosomiasis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Praziquantel 600Mg Oral Tablet x 5 + Praziquantel 600Mg Oral Tablet x 1 | Merck | Phase 2/3 | 65 |
| Biltricide (racemate praziquantel) oral tablets + Racemate Praziquantel ODT + Levo Praziquantel ODT | Merck | Phase 2 | 52 |
| praziquantel | Hikma Pharmaceuticals | Phase 3 | 72 |